IP Verse

Liquid Formulations Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide - EP3439662

The patent EP3439662 was granted to Loxo Oncology on Jul 24, 2024. The application was originally filed on Apr 4, 2017 under application number EP17718256A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3439662

LOXO ONCOLOGY
Application Number
EP17718256A
Filing Date
Apr 4, 2017
Status
Granted And Under Opposition
Jun 20, 2024
Grant Date
Jul 24, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SYNTHONApr 11, 2025HAMM & WITTKOPPADMISSIBLE

Patent Citations (162) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2013US57495-
DESCRIPTIONWO2013US61211-
DESCRIPTIONUS2005209195
DESCRIPTIONUS2006094699
DESCRIPTIONUS2009099167
DESCRIPTIONUS2009130229
DESCRIPTIONUS2009227556
DESCRIPTIONUS2010152219
DESCRIPTIONUS2010297115
DESCRIPTIONUS2010324065
DESCRIPTIONUS2011053934
DESCRIPTIONUS2011301157
DESCRIPTIONUS2014121239
DESCRIPTIONUS2015018336
DESCRIPTIONUS2015051222
DESCRIPTIONUS2015166564
DESCRIPTIONUS2015283132
DESCRIPTIONUS2015306086
DESCRIPTIONUS2016000783
DESCRIPTIONUS2016137654
DESCRIPTIONUS5844092
DESCRIPTIONUS5877016
DESCRIPTIONUS5910574
DESCRIPTIONUS6025166
DESCRIPTIONUS6027927
DESCRIPTIONUS6153189
DESCRIPTIONUS7384632
DESCRIPTIONUS7514446
DESCRIPTIONUS7615383
DESCRIPTIONUS7863289
DESCRIPTIONUS8026247
DESCRIPTIONUS8114989
DESCRIPTIONUS8299057
DESCRIPTIONUS8338417
DESCRIPTIONUS8399442
DESCRIPTIONUS8450322
DESCRIPTIONUS8501756
DESCRIPTIONUS8513263
DESCRIPTIONUS8552002
DESCRIPTIONUS8637256
DESCRIPTIONUS8637516
DESCRIPTIONUS8642035
DESCRIPTIONUS8673347
DESCRIPTIONUS8691221
DESCRIPTIONUS8791123
DESCRIPTIONUS8815901
DESCRIPTIONUS8912194
DESCRIPTIONUS8912204
DESCRIPTIONUS8933084
DESCRIPTIONUS8937071
DESCRIPTIONUS8946226
DESCRIPTIONUS9006256
DESCRIPTIONUS9035063
DESCRIPTIONUS9102671
DESCRIPTIONUS9242977
DESCRIPTIONUS9260437
DESCRIPTIONUS9273051
DESCRIPTIONWO2005044835
DESCRIPTIONWO2005051366
DESCRIPTIONWO2006087538
DESCRIPTIONWO2006115452
DESCRIPTIONWO2006123113
DESCRIPTIONWO2006131952
DESCRIPTIONWO2007002325
DESCRIPTIONWO2007002433
DESCRIPTIONWO2007022999
DESCRIPTIONWO2007057399
DESCRIPTIONWO2007087245
DESCRIPTIONWO2007110344
DESCRIPTIONWO2007136103
DESCRIPTIONWO2008031551
DESCRIPTIONWO2008037477
DESCRIPTIONWO2008058126
DESCRIPTIONWO2008079903
DESCRIPTIONWO2008079906
DESCRIPTIONWO2008079909
DESCRIPTIONWO2008080001
DESCRIPTIONWO2008080015
DESCRIPTIONWO2009007748
DESCRIPTIONWO2009012283
DESCRIPTIONWO2009013126
DESCRIPTIONWO2009014637
DESCRIPTIONWO2009017838
DESCRIPTIONWO2009053442
DESCRIPTIONWO2009071480
DESCRIPTIONWO2009092049
DESCRIPTIONWO2009118411
DESCRIPTIONWO2009143018
DESCRIPTIONWO2009143024
DESCRIPTIONWO2009152083
DESCRIPTIONWO2010031816
DESCRIPTIONWO2010033941
DESCRIPTIONWO2010048314
DESCRIPTIONWO2010058006
DESCRIPTIONWO2010111527
DESCRIPTIONWO2010145998
DESCRIPTIONWO2011006074
DESCRIPTIONWO2011092120
DESCRIPTIONWO2011133637
DESCRIPTIONWO2011146336
DESCRIPTIONWO2012034091
DESCRIPTIONWO2012034095
DESCRIPTIONWO2012053606
DESCRIPTIONWO2012101029
DESCRIPTIONWO2012101032
DESCRIPTIONWO2012109075
DESCRIPTIONWO2012113774
DESCRIPTIONWO2012116217
DESCRIPTIONWO2012139930
DESCRIPTIONWO2012143248
DESCRIPTIONWO2012152763
DESCRIPTIONWO2012158413
DESCRIPTIONWO2013014039
DESCRIPTIONWO2013050446
DESCRIPTIONWO2013050448
DESCRIPTIONWO2013059740
DESCRIPTIONWO2013074518
DESCRIPTIONWO2013102059
DESCRIPTIONWO2013174876
DESCRIPTIONWO2013183578
DESCRIPTIONWO2014011900
DESCRIPTIONWO2014019908
DESCRIPTIONWO2014072220
DESCRIPTIONWO2014078322
DESCRIPTIONWO2014078323
DESCRIPTIONWO2014078325
DESCRIPTIONWO2014078328
DESCRIPTIONWO2014078331
DESCRIPTIONWO2014078372
DESCRIPTIONWO2014078378
DESCRIPTIONWO2014078408
DESCRIPTIONWO2014078417
DESCRIPTIONWO2014078454
DESCRIPTIONWO2014160521
DESCRIPTIONWO2014184069
DESCRIPTIONWO2014194127
DESCRIPTIONWO2015017528
DESCRIPTIONWO2015017533
DESCRIPTIONWO2015057873
DESCRIPTIONWO2015058129
DESCRIPTIONWO2015061572
DESCRIPTIONWO2015108992
DESCRIPTIONWO2015112806
DESCRIPTIONWO2015124697
DESCRIPTIONWO2015161274
DESCRIPTIONWO2015161277
DESCRIPTIONWO2015175788
DESCRIPTIONWO2015191666
DESCRIPTIONWO2015191667
DESCRIPTIONWO2016011141
DESCRIPTIONWO2016011144
DESCRIPTIONWO2016011147
DESCRIPTIONWO2016022569
DESCRIPTIONWO2016027754
DESCRIPTIONWO2016075224
DESCRIPTIONWO2016077841
DESCRIPTIONWO2016081450
EXAMINATIONWO2017075107
INTERNATIONAL-SEARCH-REPORTWO2014071358
INTERNATIONAL-SEARCH-REPORTWO2015039006
INTERNATIONAL-SEARCH-REPORTWO2016077841
OPPOSITIONWO2016077841

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT)", ClinicalTrials.gov, NCT02637687, (20250325), pages 1 - 31, XP093270905-
OPPOSITION- Bauer Kurt H, Frömming Karl-Heinz, Führer Claus, "Beschreibung wichtiger Hilfsstoffe ", Pharmazeutische Technologie, Gustav Fischer, (19970101), page 183, 212, 227-229, XP093270939-
OPPOSITION- D04: Statement of Loxo Oncology before the US SEC of 15.03.2016-
OPPOSITION- Robert G. Strickley et al, "Pediatric drugs—a review of commercially available oral formulations", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, (20080501), vol. 97, no. 5, doi:10.1002/jps.21101, ISSN 00223549, pages 1731 - 1774, XP055121290
OPPOSITION- Nagasubramanian Ramamoorthy et al, "Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin‐Related Kinase Inhibitor LOXO‐101", PEDIATRIC BLOOD AND CANCER, WILEY, HOBOKEN, NJ, US, US , (20160801), vol. 63, no. 8, doi:10.1002/pbc.26026, ISSN 1545-5009, pages 1468 - 1470, XP093270911
OPPOSITION- Tony Nunn, Julie Williams, "Formulation of medicines for children", British Journal of Clinical Pharmacology, (20050601), vol. 59, no. 6, doi:10.1111/j.1365-2125.2005.02410.x, ISSN 03065251, pages 674 - 676, XP055122329
OPPOSITION- R. C. Doebele et al, "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20151001), vol. 5, no. 10, doi:10.1158/2159-8290.CD-15-0443, ISSN 2159-8274, pages 1049 - 1057, XP055374855
OPPOSITION- "TRK Inhibitor Shows Early Promise", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20160101), vol. 6, no. 1, doi:10.1158/2159-8290.CD-NB2015-165, ISSN 2159-8274, page OF4, XP009194480

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents